Amneal Pharmaceuticals (AMRX) Q4 FY25 earnings call

Amneal Pharmaceuticals delivered a strong Q4 and full year 2025, marked by robust financial growth and significant progress in portfolio expansion across complex generics, injectables, and specialty products. The company is strategically focused on vertical integration in biosimilars and advancing its GLP-1 collaboration with Pfizer, while managing near-term headwinds in its Specialty and Health Care segments to position for sustained long-term growth.